Ticker Tape by TradingView
Until recently, all cannabinoid-based medicines rely on extracting THC and CBD. this is the “grow-harvest-extract” technique. And then there are also a few companies that mix those cannabinoids, as well as some of the more rare cannabinoids.
Now, InMed Pharmaceuticals is building a potentially disruptive and transformational solution:Biosynthesis: “Cannabinoids, version 2.0”.Biosynthesis is the process that produces cannabinoids, which are biologically identical to those produced by the plant itself … without ever touching the plant! InMed has borrowed from decades of know-how in using bacteria to produce insulin and has modified this process to make cannabinoids let’s break it down.
But there are many shortcomings to these techniques. In the “grow-harvest-extract” technique, only THC and CBD can be extract, as they found in relative enough in the plant. Besides it, growing plants requires months of cycle time with heavier costs, there could be exposure to pesticides. It increases the carbon footprint, and, to be sure, there will likely arise issues related to quality control. Let’s call this method: Cannabinoids, version 1.0’.